Inappropriate prescribing of antibiotics noted in new CDC report
ATLANTA — The number of antibiotic prescriptions sought for acute respiratory infections decreased by 24% between 1993 and 2008, according to the Centers for Disease Control and Prevention’s latest "Morbidity and Mortality Weekly" report.
While this drop may be substantial, the CDC found that nearly 60% of antibiotic prescriptions for office visits among children ages 14 years and younger were for ARIs, most episodes of which do not require antibiotic therapy.
"While this decrease is encouraging, antibiotics are still prescribed too frequently for children ages 14 years and younger," CDC said. "Interventions, such as patient and healthcare provider education, offered by CDC’s Get Smart: Know When Antibiotics Work campaign, are important steps towards further reducing rates of antibiotic use among children in the United States."
The decrease in antibiotic prescriptions among those with ARIs was mostly due to decreased prescribing for patients with pharyngitis (26% decrease) and patients with nonspecific upper respiratory infections or the common cold (19% decrease).
Carole Ben-Maimon named president of Impax’s generic pharmaceutical division
HAYWARD, Calif. — Impax Labs has appointed a new president of its generic pharmaceutical division.
The drug maker said that Carole Ben-Maimon will be responsible for expanding the generic business. Recently, Ben-Maimon served as Qualitest Pharmaceuticals’ SVP corporate strategy consulting. Additionally, she served as the chairman of the board of the Generic Pharmaceutical Association from 2000 to 2003.
Ben-Maimon will report to Impax’s president and CEO Larry Hsu.
Study: Greater consumer understanding of personal care active ingredients drives product development
PARSIPPANY, N.J. — The U.S. specialty actives market is on the rise as consumers gain a better understanding of personal care active ingredients and increasingly demand products that deliver results, according to a recent report from consulting and research firm Kline & Co.
The specialty actives market in the United States reached nearly $240 million in 2010 and is expected to grow at an annual growth rate of 3.8% through 2015, according to Kline’s recently published study “Specialty Actives in Personal Care 2011: U.S. Market Analysis and Opportunities.”
“The increasing average age of a U.S. citizen and desire to look younger has raised consumer expectations for efficacy of active ingredients resulting in functionality becoming increasingly important,” stated Anna Ibbotson, industry manger at Kline’s chemicals and materials practice. “Consumers want to see results, and this is reflected in the trend toward more effective finished personal care products.”
She added that, for example, “in the natural products arena, the presence of plant-based ingredients in the formulation used to be enough to encourage personal care consumers to purchase the products. However, consumer awareness concerning product activity has increased, and the product’s function and efficacy are regarded as at least as important as the active ingredient source.”
As the demand for natural concepts continues, this will sustain growth in the botanicals segment, which is currently the largest specialty actives category, with 38% market share, according to Kline. The fastest-growing category is biotechnology products, with an estimated compound annual growth rate of 4.5% from 2010 to 2015. From the functionality perspective, the largest and the fastest-growing group is anti-aging — which includes subfunctionalities, such as anti-wrinkle, firming, moisturizing, skin radiance and age spots — accounting for 56% of the market in 2010.